ZymoGenetics Sues Bristol-Myers Squibb in Patent Dispute
ePT--the Electronic Newsletter of Pharmaceutical Technology
ZymoGenetics (Seattle, WA) has sued Bristol-Myers Squibb (New York, NY) over alleged infringement of ZymoGentics's fusion-protein technology patents.
ZymoGenetics (Seattle, WA, www.zymogenetics.com) has sued Bristol-Myers Squibb (New York, NY, www.bms.com) over alleged infringement of ZymoGentics’s fusion-protein technology patents. ZymoGenetics filed the lawsuit in the US District Court for the District of Delaware and is seeking injunctive relief and damages.
“We have a number of patents on fusion-protein technology, which we believe are being infringed by Bristol-Myers Squibb,” said Bruce L.A. Carter, PhD, president and chief executive officer of ZymoGenetics. “It is important that ZymoGenetics protect its intellectual property rights for technology that it expended significant resources in developing, and we will enforce our patents through litigation when necessary.”
Amgen (Thousand Oaks, CA, www.amgen.com) and Regeneron Pharmaceuticals (Tarrytown, NY, www.regeneron.com) previously have licensed ZymoGenetics’s fusion-protein patents.
Further details about the lawsuit were not provided. At press time, Bristol-Myers Squibb had not commented on the lawsuit.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
